Top 10 Pharma Chooses D360 Software to Easily Generate Cross-Study Data Views and Analysis of Preclinical Safety Data.
ST. LOUIS, MO – 2012年1月17日 – Certara™, a leading provider of software and services to improve productivity and decision-making from discovery through clinical development, announced today that a Top 10 pharma Company, after completing an extensive competitive review process, has selected D360 as its enterprise solution for conducting single-study and cross-study search and analysis of preclinical safety data.
In making the announcement, Certara’s Senior Vice President and General Manager, Dr. Daniel Weiner, said, “Accessing and analyzing preclinical safety data has become exceedingly difficult as the amount of study data has grown exponentially and acquisitions have resulted in heterogeneous informatics environments. Certara is very pleased to partner with a world renowned pharma organization to deploy a pioneering solution to this important industry problem through a combination of D360 and Certara’s knowledge of preclinical informatics.”
D360 is used by scientists to integrate and provide robust access to multiple types of data, regardless of where it resides, including chemical, biological, PK/PD, safety data and more. “Many pharma and biotech research teams are now looking for improved data access, analysis, and visualization solutions for both internal and outsourced data. Certara is very pleased that another Top 10 Pharma company has been added to the growing family of D360 customers to address these challenges,” said James Hayden, Senior Vice President of Sales and Marketing for Certara. “By integrating D360 with preclinical safety data, Certara now supports integration from discovery through development, realizing our vision of support for translational science workflows. We truly feel that these efforts will help to catalyze new efficiencies in the industry as we start to break down the barriers between the drug development silos and enable the cross discipline communication that is critical to a more effective drug development process.”
More information about D360’s data integration, data mining, data visualization and analysis capabilities can be found by contacting Certara.
Certara is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara unites Tripos (http://www.tripos.com) and Pharsight Corporation (http://www.pharsight.com). Tripos provides innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery. Pharsight provides software and consulting services to improve productivity and decision-making in preclinical and clinical drug development.
For More Information Contact:
Director, Software Marketing
314-951-3310 or email@example.com